Aesthetic manufacturer Teoxane has relaunched Teosyal RHA 3 in a new 1.2ml syringe format.
The company shares that the new, larger syringe will contain the same RHA 3 formulation, aiming to provide practitioners with 20% more product.
Formulated with Teoxane’s Resilient Hyaluronic Acid (RHA) technology, Teosyal RHA 3 is a dermal filler supported by scientific research and indicated for use in the perioral region (philtrum, oral commissures, lips), cheeks, nasolabial folds, marionette lines, nasojugal groove, jawline and chin, according to Teoxane.
Joanna Underhill, general manager for Teoxane UK&I, commented, “Teosyal RHA 3 has long been recognised for its ability to provide natural-looking volume with resilience and flexibility. This redesign brings greater efficiency and more treatment possibilities to support practitioners in delivering tailored treatments for a wider variety of patient needs and facial indications, leading to exceptional outcomes for patients.”